Back to Results
First PageMeta Content
Experimental cancer treatments / Oncolytic virus / Immunology / Medical research / Immunotherapy / Gene therapy / Reolysin / Medicine / Biology / Viruses


FINAL FOR DISTRIBUTION PSIOXUS THERAPEUTICS RAISES A £25M SERIES C INVESTMENT TO PROGRESS ONCOLYTIC VIRUS PLUS CHECKPOINT INHIBITOR COMBINATION STUDY IN METASTATIC COLORECTAL CANCER OXFORD, UK – 19 May 2015 – PsiOxu
Add to Reading List

Document Date: 2015-05-19 03:49:40

Open Document

File Size: 246,17 KB

Share Result on Facebook

City

Vienna / OXFORD / /

Company

CHECKPOINT / Woodford Patient Capital Trust / GlaxoSmithKline / Lundbeckfond Ventures / PsiOxus Therapeutics Ltd. / Investment Management Woodford Investment Management / SROne / Mercia Technologies / Invesco / /

Country

Austria / United Kingdom / /

Currency

GBP / CAD / /

Event

Funding / /

IndustryTerm

virus product / stage biotechnology / /

MedicalCondition

colorectal tumours / cancer / selective infection / enadenotucirev infection / C INVESTMENT TO PROGRESS ONCOLYTIC VIRUS PLUS CHECKPOINT INHIBITOR COMBINATION STUDY IN METASTATIC COLORECTAL CANCER OXFORD / tumour / metastatic colorectal cancer / /

MedicalTreatment

gene therapy / intravenous infusion / /

Person

Theodora Harold / John Beadle / Founding / /

Position

Chief Financial Officer / CEO / internal candidate / /

Product

AbEnAd / /

Technology

gene therapy / antibodies / /

SocialTag